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Significance of the Topic:  
Understanding how the effects of long-duration spaceflight (~6-months) might increase fracture risk in the 
younger-aged, physically-fit astronaut is challenging.   Most of our skeletal data have been acquired from long-
duration astronauts, crewmembers who typically serve on 120-180 day missions aboard the International Space 
Station (ISS).  Astronaut biomedical data are predominantly 2-d measurements from DXA scans because this is a 
required clinical test at Johnson Space Center.  Data from these clinical tests, and some data from research studies, 
are what NASA evaluates to define a risk for fracture in astronauts, both during a mission and long-term health. To 
date, the agency considers the risk for fracture during spaceflight to be of high (severe) consequence but of low 
probability (<0.1%) while the risk for fracture in during long-term health to be of medium consequence 
(interventions available) and medium probability (<1%). These risks are considered acceptable. 
Notably, there are minimal data to suggest that postflight fractures in long-duration astronauts are directly due to 
spaceflight exposure.  Analyses by NASA epidemiologists and by biomedical engineers suggest that postflight 
fracture incidence in astronauts is consistent with a physically-active terrestrial population with no exposure to 
spaceflight.  The epidemiological data to-date may be considered insufficient (low # and younger-aged subjects, 
limited follow-up time) to assess a fracture risk with reliability.  In the absence of fracture evidence to substantiate 
a risk, it may be more useful to maintain astronauts at baseline (preflight) level of skeletal health during a mission.   
This lecture will present data from astronauts that affirms that 1) the maintenance of skeletal health during the 
future 3-year Mars mission will require an anti-resorptive therapy and 2) the risk for fracture during long-term 
health cannot be defined by the DXA clinical test alone. 
Learning Objectives:  
As a result of participating in this session, attendees should be able to: 
• Describe the skeletal effects of spaceflight (~6-months in duration) on bone biochemistry and 
densitometry of astronauts. 
• Recognize the limitations of NASA’s clinical surveillance plan for skeletal health of astronauts. 
• Understand the bias of NASA stakeholders to accepting current terrestrial therapies for mitigating bone 
loss. 
  
https://ntrs.nasa.gov/search.jsp?R=20200001704 2020-03-28T19:13:10+00:00Z
Points of Interest: 
                                          Cohort of Long Duration Astronautsa 
Average Spaceflight Duration (days): 161 ± 39 (range 49-340) 
Average Age (years): 47 ± 5  (36 – 58) 
Male:Female ratio : 76:16 or 4.8:1  
Total # per Astronauts in Corps: 92 of 365 
# Repeat Fliers: 12 (10 with 2 flights; 2 with 3 flights) 
Body Mass Index (BMI ):  Male BMI 25.8 ± 2.2 (range 21.2 to 32.6)  
Female BMI 20.1 ± 2.6 (range 20.1 to 28.5) 
Body Mass (kg): Males: 81 ± 9 (range 63 to 103) 
Females : 66 ± 8 (54 to 83) 
Height (cm): Males: 177 ± 6 (163 to 188) 
Females : 169 ± 4 (163 to 178) 
Body Fat (%): Males:  24 ± 4 (14 to 32)   
Females:  30 ± 6 (22 to 44) 
a: Tabulated demographics includes astronauts of the US and International Partners 
(Japanese Space Agency; European Space Agency, Canadian Space Agency) during eras of 
Mir space craft (from 1995-1998) and  the ISS (from 2000-2018).  Table does not include 
data from Short Duration Astronauts who flew exclusively on spaceflights (less than 30 
days). 
 
   
1 Pre vs. Post, P < 0.05 
2 Delta change vs. ARED, P < 0.05 
Denotes Least Significant 
Change     
Changes in DXA areal BMD (aBMD) after Spaceflight.  DXA measurements of aBMD for total hip (TotHip), 
trochanter (Troch), femoral neck (FNeck) and lumbar spine (LSpine) were acquired before and after spaceflight, 
and the percentage change from preflight to postflight over the entire spaceflight is plotted by group for skeletal 
regions of interest.  Significant delta changes are denoted for within-group comparisons (* P<0.05, pre vs. post) and 
for between-group comparisons (** P<0.05 below line comparing Pre-ARED vs. ARED and ARED vs. BP+ARED).  The 
measurement errors (“least significant change”) for the DXA measurements at JSC are denoted by shaded areas.  
Pre-ARED resistive exercise with maximum 300 lb-f loading; ARED – Advanced Resistive Exercise Device up to 600 
lb-f loading; BP+ARED – Combined bisphosphonate (alendronate) and ARED countermeasures. 
  
 
 
 
Changes in QCT Trabecular vBMD after Spaceflight for the Hip and its Sub-regions.   The QCT measurement error 
for trabecular vBMD is approximated by shaded areas [Li, 2006; Carballido-Gamio, 2015]. The effectiveness of in-
flight countermeasures (Pre-ARED, ARED and BP+ARED) was assessed for significant mitigation of group mean 
declines from preflight. Significant delta changes are denoted for within-group comparisons (* P<0.05, pre vs. post) 
and for between-group comparisons (** P<0.05 below line comparing Pre-ARED vs. ARED and ARED vs. BP+ARED). 
Pre-ARED resistive exercise with maximum 300 lb-f loading; ARED – Advanced Resistive Exercise Device up to 600 
lb-f loading; BP+ARED – Combined bisphosphonate (alendronate) and ARED countermeasures. 
1   Pre vs. Post, P < 0.05 
2   Delta change vs. ARED, P < 0.05 
  
Surveillance of ISS Astronauts after Return to Earth.  QCT scans were performed i) once prior to launch (6-1 month 
Pre –flight), ii) ~1 wk after return (R + 5), iii) at approximately 1 year after return (R + 1 yr) and iv) at approximately 
2 years after return for 5 of 10 astronauts in a pilot study of recovery surveillance.  QCT scans were performed 
using a clinical QCT scanner at hospitals local to JSC [Leblanc, 2013].   Seven astronauts were treated with the oral 
bisphosphonate alendronate. 
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